Sign in
Taking people in United StatesPhase 3

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

Key facts

Who runs it
Hoffmann-La Roche
Where
Bardstown, Beaumont, Birmingham, Chamblee, Charleston, Dallas, Dayton, Grand Island, Harrisburg, Houston, Idaho Falls, Kingwood, Lafayette, Las Vegas, Lawrenceville, Macon, Miami, Middleburg Heights, Mishawaka, Pensacola, Richardson, San Antonio, Slidell, Smithfield, Sugar Land, and West Jordan, United StatesSee the 28 sitesAlso in 3 other countries, 18 sites
Status
Recruiting
Phase
Phase 3
People taking part
1,100 people, planned
Started
22 Nov 2023
Expected to end
30 Jun 2027
Type of study
Interventional
Treatments tested
  • Baloxavir Marboxil
Record updated
23 October 2026

Who can take part

Age
3 weeks to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Participants with symptoms suggestive of influenza based on investigator's judgement with diagnosis confirmed by a positive local influenza test within 24 hours before full study screening
  • Participants with a negative severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) test within 48 hours before full study screening
  • Time interval between onset of influenza symptoms and the start of pre-dose examinations at screening is 48 hours or less
  • [A] IP:
  • Eligible to take part in Part A
  • Lives in a household with a HHC willing to be recruited as full HHC; [B] HHCs:
  • Each HHC living in the home of an IP at the time of IP treatment must be screened for partial or full-study HHC eligibility; [C] Partial HHC:
  • Starts screening within 1 calendar day after IP treatment
  • Negative influenza and SARS-CoV-2 test at screening after IP's treatment with baloxavir marboxil
  • HHC lives in a household where 1 or more HHCs meet the full-study HHC requirements AND at least 1 full-study HHC has not received the influenza vaccine within 6 months prior to screening
  • HHC lives in a household where 1 or more HHCs meet the full-study HHC requirements, and at least 1 full-study HHC has not received the influenza vaccine within 6 months prior to screening
  • HHC lives with other HHCs (if applicable) who fulfill all the "partial HHC" criteria; [D] Full-study HHC:
  • Fulfills the "partial HHC" criteria
  • Agrees to participate in the full study
  • Will reside in the IP's house for at least 12 of the next 15 days and will be present for scheduled study visits
  • No influenza symptoms within 7 days prior to screening
  • Does not have a moderate or worse active infections or infections requiring systemic or otherwise internally administered or otherwise internally administered antibiotic/antiviral/antifungal therapy

Who cannot take part

  • Severely immunocompromised participants (including participants receiving immunosuppressant therapy, or those with cancer or human immunodeficiency virus [HIV] infection) as defined by the investigator
  • Participants with concurrent (non-influenza) infections requiring systemic anti-microbial and/or anti-viral therapy at the pre-dose examinations
  • Treatment with baloxavir marboxil, peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to screening
  • Treatment with an investigational influenza-specific monoclonal antibody within 6 months or 5 half-lives, whichever is longer, prior to screening
  • Treatment with an investigational therapy within 30 days or 5 half-lives, whichever is longer, prior to screening
  • Participants with severe influenza virus infection requiring inpatient treatment
  • Known hypersensitivity to baloxavir marboxil or the drug product excipients
  • Females who have commenced menarche (i.e., child-bearing potential)
  • IPs who fulfil an exclusion criterion for Part A
  • HHCs deemed to require influenza post-exposure prophylaxis with influenza antiviral treatment due to their risk of developing influenza-related complications in accordance with local guidelines or clinical practice
  • HHCs diagnosed with influenza by health care professional in the past 4 weeks

Where in United States

Also in 3 other countries, 18 sites

  • Kentucky Pediatric Research CenterBardstown, United StatesTaking people
  • Tekton Research - BeaumontBeaumont, United StatesNo longer taking part
  • Central Alabama ResearchBirmingham, United StatesTaking people
  • Tekton Research - Chamblee GeorgiaChamblee, United StatesNo longer taking part
  • Coastal Pediatric ResearchCharleston, United StatesNo longer taking part
  • Oak Cliff Research Company, LLCDallas, United StatesNo longer taking part
  • Ohio Pediatric Research AssociationDayton, United StatesNo longer taking part
  • Velocity Clinical Research - Grand IslandGrand Island, United StatesNo longer taking part
  • Harrisburg Family Medical CenterHarrisburg, United StatesTaking people
  • Pioneer Research SolutionsHouston, United StatesTaking people
  • Mercury Clinical ResearchHouston, United StatesNo longer taking part
  • Clinical Research PrimeIdaho Falls, United StatesTaking people
  • Frontier Clinical Research, LLCKingwood, United StatesNo longer taking part
  • Velocity Clinical Research, LafayetteLafayette, United StatesTaking people
  • Machuca Family MedicineLas Vegas, United StatesNo longer taking part
  • Tekton Research LawrencevilleLawrenceville, United StatesNo longer taking part
  • Velocity Clinical Research at Primary Pediatrics MaconMacon, United StatesNo longer taking part
  • Kendall South Medical Center, IncMiami, United StatesTaking people
  • Helios Clinical Research, Inc (former Ventavia Research Group)Middleburg Heights, United StatesTaking people
  • Mishawaka Osteopathic ClinicMishawaka, United StatesTaking people
  • Avanza Medical Research CenterPensacola, United StatesNo longer taking part
  • Oak Cliff Research Company, LLCRichardson, United StatesNo longer taking part
  • Sun Research InstituteSan Antonio, United StatesNo longer taking part
  • Tekton ResearchSan Antonio, United StatesNo longer taking part
  • Velocity Clinical Research, SlidellSlidell, United StatesNo longer taking part
  • Frontier Clinical ResearchSmithfield, United StatesTaking people
  • Siena Research NetworkSugar Land, United StatesTaking people
  • Velocity Clinical Research, Salt Lake CityWest Jordan, United StatesNo longer taking part

About the trial

What the trial wants to find out

This study consists of two parts: Part A Surveillance and Part B Transmission.

Read full original descriptionShow less

The main purpose of Part A is to evaluate the prevalence of pre-dose and treatment-emergent amino acid substitutions in pediatric participants' <12 years with influenza treated with baloxavir marboxil.

Part B will include a subset of Part A participants who have household contacts (HHCs) recruited to the study. Part B will evaluate the incidence of onward influenza transmission from pediatric index participants (IPs) under 5 years of age and those aged 5 to under 12 years, treated with baloxavir marboxil, to their HHCs. Participants will no longer be enrolled to Part B Transmission as per protocol version 3.

The group in the trial

  • Baloxavir MarboxilTreatment being tested

    Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight and age). HHCs related to IPs will be enrolled but will not receive treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase IIIb Multicenter, Single-arm, Open-label Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Patients With Influenza and Transmission of Influenza to Household Contacts
Record updated
23 October 2026